strengths container graph

Our Core Strengths Create the Foundation for Diversified Durable Growth and Dependable Performance

As a global medical technology innovator leading the way in women’s health, Hologic delivers life-changing and lifesaving detection, diagnostic and treatment solutions. Our products are rooted in The Science of Sure®, our promise to deliver world-class certainty, precision and quality to healthcare providers and their patients.

DIVISION CORE BUSINESS PRODUCTS KEY GROWTH-DRIVING PRODUCTS

DIAGNOSTIC
SOLUTIONS

diagnostic Solutions white pie
panther
aptima ThinPrep

Panther® • Aptima® STI Assays •

ThinPrep® Pap Test and Cytology Instruments
aptima boxes

Aptima BV and CV/TV Assays

  • Molecular nucleic acid amplification tests.
  • Used to detect the three leading causes of vaginosis and vaginitis: bacterial vaginosis, candida vaginitis and trichomoniasis.
Breast Test

Breast Cancer Index™ Text

  • Used to predict which breast cancer patients are likely to benefit from an extended endocrine therapy.
  • The only test of its kind recognized by key medical societies.
  • Reimbursed by Medicare and key insurance providers.
Aptima Quant

Aptima Quant Virology Assays

  • Highly accurate assays for HIV-1, HCV and HBV.
  • Life-changing testing for viruses affecting patients worldwide, including millions in sub-Saharan Africa, whom we support throught Hologic's Global Access Initiative.
Panther Fusion

Panther Fusion® and Panther Scalable Solutions

  • Provide access to Hologic's full menu of molecular diagnostic tests.
  • Allow labs to expand existing molecular testing capabilities without a major staffing investment.
  • Increase flexibility, capacity and walkaway time.

Genius Digital Cytology

  • First CE-marked digital cytology platform to combine an artificial intelligence (AI) algorithm with advanced volumetric imaging technology.
  • Comprehensive cervical cancer screening portfolio — from sample collection to digital diagnosis.
  • Helps healthcare providers by supplying critical information needed to help guide earlier detection and better treatment decisions.

BREAST & SKELETAL
HEALTH SOLUTIONS

breast and SKELETAL white pie
3Dimensions
LOcalizer Affirm Breast System
Trident System

3Dimensions® • Affirm ® Breast Biopsy Systems •

Trident® Specimen Radiography System •

LOCalizer™ Wire-free Guidance System
Brevera

Brevera®

  • Breast biopsy system provides real-time imaging and analysis of specimens.
  • Intuitive user interface and automated specimen collection.
  • Streamlined, accurate procedures reduce a patient's time under breast compression.
Genius AI

Genius AI™

  • Supports radiologists in improving accuracy and consistency of breast cancer detection.
  • Designed to maximize effectiveness of digital breast tomosynthesis (3D mammography).
  • Software is fully integrated on 3Dimensions systems.
Interventional Needles

Interventional Needles

  • Portfolio of tissue-acquisition needles that function with stereotactic and ultrasound systems.
  • Provide ease of use with world-class accuracy, consistency and efficiency.
Tissue Markers Tissue Markers-2

Tissue Markers

  • Serve a fast-expanding market segment of products for breast-conserving surgery.
  • Minimally invasive innovations that enhance imaging and radiation treatment.
  • Completed Endomagnetics acquisition ni July 2024, adding additional interventional localization and tracing products to portfolio.

GYN SURGICAL
SOLUTIONS

GYN SURGICAL white pie
Novasure Image MyoSure

NovaSure® • MyoSure®
Fluent

Fluent®

  • Fluid management system for hysteroscopies.
  • Provides simplified set-up and operation.
  • Advanced technology designed to increase clinical confidence.
Acessa

Acessa®

  • Minimally invasive, laparoscopic radiofrequency ablation system.
  • Treats nearly all types of fibroids.
  • 99% of commercially insured patients have coverage for the Acessa procedure.
CollSeal

CoolSeal® Portfolio

  • Utilizes gold-standard efficacy of advanced bipolar RF vessel sealing technology.
  • Versatile applications for both pediatric and gynecologic procedures.
  • Devices cut and dissect with precision in tight spaces and with minimal thermal footprint.
Omni Hysteroscope

Omni® Hysteroscope

  • Three interchangeable sheaths to enable flexible diagnosis and treatment with a single instrument.
  • Provides a clear view of the cervical canal and uterine cavity.

Enabling healthier lives everywhere, every day.

Growing Performance, Growing Impact and Growing Recognition

Revenue Highlights 1Q25

Non-GAAP Revenue ($M) 1Q25 Reported ∆
Vs 1Q24 		CC ∆ Vs 1Q24
Diagnostics $470.6 5.1% 5.2%
Organic Diagnostics ex. COVID-192 $422.9 9.0% 9.1%
Organic Molecular Diag. ex. COVID-19 $297.4 10.9% 11.0%
Breast Health $369.1 -2.3% -2.1%
Organic Breast Health2 $354.6 -5.9% -5.8%
GYN Surgical $166.3 2.5% 2.5%
Skeletal Health $15.8 -37.8% -37.4%
Total Revenue $1,021.8 0.9% 1.0%
Organic Revenue2 $1,003.2 -0.1% 0.0%
Organic ex. COVID-193 $959.6 0.7% 0.8%
US Revenue $757.9 0.6% -
Intl Revenue $263.9 1.7% 2.1%

Financial Overview 1Q25

Non-GAAP
In Millions ex. EPS 		1Q25 ∆ vs. 1Q24
Revenue ($M) $1,021.8 0.9%
Organic Revenue2 $1,003.2 -0.1%
Organic ex. COVID-193 $959.6 0.7%
Gross Margin 61.6% 80 bps
Operating Expenses $329.0 0.5%
Operating Margin 29.4% 90 bps
Net Margin 23.4% 10 bps
Diluted EPS $1.03 5.1%
Adjusted EBITDA $326.0 3.5%

Financial Guidance for Second Quarter Fiscal 2025

Q2 2025 Guidance $ Reported vs. 2Q24 CC vs. 2Q24 Organic vs. 2Q24 Organic ex. COVID-19 vs. 2Q24
Revenue ($M) $995 - $1,005 (2.2%) to (1.3%) (1.3%) to (0.3%) (2.9%) to (1.9%) (1.1%) to (0.1%)
GAAP EPS $0.80 - $0.83 11.1% to 15.3%
Non-GAAP EPS $1.00 - $1.03 (2.9%) to 0.0%

Financial Guidance for Full Year Fiscal 2025

Fiscal 2025 Guidance $ Reported CC vs. FY24 Organic ex. Organic ex. COVID-193
Revenue ($M) $4,050 - $4,100 0.5% to 1.7% 1.3% to 2.5% (0.2%) to 1.0% 0.9% to 2.2%
GAAP EPS $3.51 - $3.61 5.7% to 8.7%
Non-GAAP EPS $4.25 - $4.35 4.2% to 6.6%
Capital Deployment Priorities
  • Expect strong cash flow in our fiscal second quarter and the full year 2025
  • Continuing to invest in ourselves through investments and share repurchases.
  • Business development priorities:
- Tuck-in acquisitions - Attractive revenue, EPS growth rates - Attractive ROIC - Leverage existing strengths

Financial Results

Net Debt & Leverage Ratio

Revenue & CC Growth Rates

Non-GAAP EPS & Growth Rates

2024 Divisional Revenue by Geography

Adjusted Operating Cash Flow4

ROIC

  1. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA.
  2. Organic revenue excludes Endomagnetics, and divestited Blood and SSI businesses.
  3. Total organic revenue excluding COVID-19.
  4. Operating cash flow adjusted for one-time tax and litigation items.

© 2024 Hologic Inc. All rights reserved. Hologic and The Science of Sure are trademarks of Hologic Inc. Other trademarks, logos, and slogans registered or used by Hologic and its divisions and subsidiaries in the United States and other countries include, but are not limited to, the following: 3Dimensions, Acessa, Affirm, Aptima, Breast Cancer Index, Brevera, CoolSeal, Dimensions, Endomagnetics, Fluent, LOCalizer, MyoSure, NovaSure, Novodiag, Panther, Panther Fusion, ThinPrep. All other trademarks, registered trademarks and product names are the property of their respective owners.

Purpose-Driven Company

Through our substantial commitment to R&D innovation, we generate strong financial results, allowing us to invest in groundbreaking health initiatives for women and underserved communities.

Purpose Drive Graph
Global Health:
  • Hologic Global Women’s Health Index represents the views of 94% of the world’s women and girls aged 15 or older.
  • Global Access Initiative provides cost-effective, high-quality diagnostic testing across sub-Saharan Africa.
  • Philanthropic donations aid charitable groups focused on women’s health, STEM education and social equity.
Global Headquarters:

Marlborough, Massachusetts, US.